WINSTON-Kucera Pharmaceutical Co. has been issued a patent by entitled “Compositions and Methods for Double-targeting Virus Infections and Targeting Cancer Cells.”

The technology within this patent can improve the efficacy and safety of a number of antiviral, anticancer, and other therapeutic compounds, Kucera says. It is the sixth U.S. patent for the company.

“Our intellectual property base continues to grow,” said Russ Read, chief executive officer of Kucera. “Our team is highly focused on building value through Kucera chemistry and its initial applications in virology and cancer.”

Based in Winston-Salem, Kucera is a 2001 spin-off of Wake Forest University Health Sciences and the University of North Carolina at Chapel Hill. The company has in development patented antiviral small molecules, as well as anticancer agents.